Back to Search
Start Over
Pertuzumab for the treatment of breast cancer
- Source :
- Expert Review of Anticancer Therapy. 20:85-95
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- Introduction: Pertuzumab, a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), inhibits the heterodimerization of HER2 with other HER receptors. It has been approved both by the Food and Drug Administration and the European Medicine Agency in the metastatic, neoadjuvant and adjuvant setting.Areas covered: This review analyses and discusses preclinical and clinical studies of pertuzumab in breast cancer. In this article, we review the status of pertuzumab, the completed and ongoing trials, and its safety.Expert opinion: Pertuzumab is a key drug for the treatment of HER2-positive metastatic or early breast cancer. However, it is imperative to identify patients that will need dual-targeting and mechanisms of resistance. Moreover, the value of pertuzumab beyond progression needs to be evaluated.
- Subjects :
- 0301 basic medicine
Drug
Oncology
medicine.medical_specialty
Receptor, ErbB-2
media_common.quotation_subject
medicine.medical_treatment
Breast Neoplasms
Antibodies, Monoclonal, Humanized
Food and drug administration
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Breast cancer
Internal medicine
medicine
Humans
Pharmacology (medical)
skin and connective tissue diseases
Human Epidermal Growth Factor Receptor 2
Neoadjuvant therapy
media_common
business.industry
medicine.disease
Metastatic breast cancer
Neoadjuvant Therapy
030104 developmental biology
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
Female
Pertuzumab
business
Adjuvant
medicine.drug
Subjects
Details
- ISSN :
- 17448328 and 14737140
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Expert Review of Anticancer Therapy
- Accession number :
- edsair.doi.dedup.....4c2202d21df26993d0db300220a1e634